視網膜脫離|細菌性肺炎藥物Fetroja(cefiderocol)的作用機制、療效及安全性( 二 )


參考來源:
[1
‘Shionogi Announces FDA Approval of Fetroja? (cefiderocol) for the Treatment of Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia’ , 新聞發布 。 Shionogi & Co. Ltd.;2020年9月29日發布 。
[2
Langford BJ So M Raybardhan S et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26(12):1622-1629.
[3
Garcia-Vidal C Sanjuan G Moreno-Garcia E et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021;27(1):83-88.
注:本文旨在介紹醫藥健康研究 , 不作任何用藥依據 , 具體用藥指引 , 請咨詢主治醫師 。